title: Twelve Core Template Prostate Biopsy is an Unreliable Tool to Select Patients Eligible for Focal Therapy.
abstract: BACKGROUND
  To determine whether unilateral prostate cancer diagnosed at 12-core prostate biopsy harbours relevant prostate cancer foci in contralateral lobe in cases eligible for hemiablative focal therapy.
  
  
  METHODS
  We analysed 112 radical prostatectomies of unilateral Gleason 6/7 prostate cancer based on prostate biopsy information. The presence of significant prostate cancer foci and/or the index lesion in the contralateral lobe is described. A subanalysis is performed in cases of Gleason score 6 and in cases of very-low-risk prostate cancer.
  
  
  RESULTS
  Contralateral prostate cancer was present in 69.6% of cases, fulfilling significant prostate cancer criteria in 33% and being the index lesion in 32%. No significant differences were found when analysing the Gleason 6 group (73% contralateral prostate cancer, 34% significant prostate cancer and 35% index lesion) or the very-low-risk prostate cancer group (80% contralateral prostate cancer, 29% significant prostate cancer and 45% index lesion).
  
  
  CONCLUSIONS
  The assumption of unilateral prostate cancer based on 12-core template prostate biopsy information is unreliable. In about one third of the cases, there will be focus of significant prostate cancer or the index lesion in the contralateral lobe. This information should be taken into account when hemiablative focal therapies are considered.
authors.affiliation: Department of Urology, Hospital del Mar, Barcelona, Spain.
authors.forename: Lluís
authors.initials: L
authors.lastname: Fumadó
authors.forename: Lluís
authors.initials: L
authors.lastname: Cecchini
authors.forename: Nuria
authors.initials: N
authors.lastname: Juanpere
authors.forename: Anna
authors.initials: A
authors.lastname: Ubré
authors.forename: Jose Antonio
authors.initials: JA
authors.lastname: Lorente
authors.forename: Antonio
authors.initials: A
authors.lastname: Alcaraz
mesh_terms: D000368:Aged; D062005:Biopsy, Large-Core Needle / Q000379:methods*; D055088:Early Detection of Cancer; D006801:Humans; D008297:Male; D008875:Middle Aged; D060787:Neoplasm Grading; D018579:Patient Selection; D011467:Prostate / Q000473:pathology*; D017430:Prostate-Specific Antigen / Q000097:blood; D011468:Prostatectomy; D011471:Prostatic Neoplasms / Q000175:diagnosis / Q000628:therapy*; D012189:Retrospective Studies
chemical_list: D017430:Prostate-Specific Antigen